Colorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation

Trends in Cancer

Volumn 2, Issue 9, 2016, Pages 505-518

  Fessler, Evelyn ^a,b,c   Medema, Jan Paul ^a,b,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b University of Amsterdam   (Netherlands)

^c Cancer GenomiCs Netherlands   (Netherlands)

Author keywords

adenoma carcinoma sequence; cancer subtypes; cell of origin; colorectal cancer; tumor microenvironment

Indexed keywords

CANCER CELL; CANCER CLASSIFICATION; CARCINOGENESIS; COLORECTAL CANCER; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; CLASSIFICATION; COLORECTAL TUMOR; GENETICS;

ANIMALS; COLORECTAL NEOPLASMS; HUMANS; TUMOR MICROENVIRONMENT;

EID: 84989953478     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.07.008     Document Type: Review

References (114)

1. 1 Popat, S., et al. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23 (2005), 609–618.
2. 2 Sargent, D.J., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 28 (2010), 3219–3226.
3. 3 Ogino, S., et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58 (2009), 90–96.
4. 4 Samowitz, W.S., et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 65 (2005), 6063–6070.
5. 5 Sinicrope, F.A., et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology 148 (2015), 88–99.
6. 6 Popovici, V., et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J. Clin. Oncol. 30 (2012), 1288–1295.
7. 7 Tian, S., et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut 62 (2012), 540–549.
8. 8 Wang, X., et al. Dissecting cancer heterogeneity–an unsupervised classification approach. Int. J. Biochem. Cell Biol. 45 (2013), 2574–2579.
9. 9 Schlicker, A., et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med. Genomics, 5, 2012, 66.
10. 10 Perez-Villamil, B., et al. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer, 12, 2012, 260.
11. 11 Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (2012), 330–337.
12. 12 De Sousa E Melo, F., et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat. Med. 19 (2013), 614–618.
13. 13 Sadanandam, A., et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 19 (2013), 619–625.
14. 14 Budinska, E., et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J. Pathol. 231 (2013), 63–76.
15. 15 Roepman, P., et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int. J. Cancer 134 (2014), 552–562.
16. 16 Marisa, L., et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med., 10, 2013, e1001453.
17. 17 Guinney, J., et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21 (2015), 1350–1356.
18. 18 Fearon, E.F., Vogelstein, B., A genetic model for colorectal tumorigenesis. Cell 61 (1990), 759–767.
19. 19 Gerlinger, M., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366 (2012), 883–892.
20. 20 Sottoriva, A., et al. A big bang model of human colorectal tumor growth. Nat. Genet. 47 (2015), 209–216.
21. 21 Patel, A.P., et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344 (2014), 1396–1401.
22. 22 Dunne, P.D., et al. Challenging the cancer molecular stratification dogma: intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic value in colorectal cancer. Clin. Cancer Res., 2016 (in press).
23. 23 Lei, Z., et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology 145 (2013), 554–565.
24. 24 Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513 (2014), 202–209.
25. 25 Hoadley, K.A., et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158 (2014), 929–944.
26. 26 Garnett, M.J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483 (2012), 570–575.
27. 27 Barretina, J., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483 (2012), 603–607.
28. 28 Medico, E., et al. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nat. Commun., 6, 2015, 7002.
29. 29 Sato, T., Clevers, H., Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science 340 (2013), 1190–1194.
30. 30 van de Wetering, M., et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161 (2015), 933–945.
31. 31 Bardelli, A., et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 3 (2013), 658–673.
32. 32 Jin, K., et al. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin. Trans. Oncol. 12 (2010), 473–480.
33. 33 Tentler, J.J., et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9 (2012), 338–350.
34. 34 Visvader, J.E., Cells of origin in cancer. Nature 469 (2011), 314–322.
35. 35 Barker, N., et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457 (2009), 608–611.
36. 36 Zhu, L., et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 457 (2009), 603–607.
37. 37 Vermeulen, L., Snippert, H.J., Stem cell dynamics in homeostasis and cancer of the intestine. Nat. Rev. Cancer 14 (2014), 468–480.
38. 38 Schwitalla, S., et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152 (2013), 25–38.
39. 39 van der Heijden, M., et al. Bcl-2 is a critical mediator of intestinal transformation. Nat. Commun., 7, 2016, 10916.
40. 40 Friedmann-Morvinski, D., et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 338 (2012), 1080–1084.
41. 41 Lim, E., et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 15 (2009), 907–913.
42. 42 Molyneux, G., et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7 (2010), 403–417.
43. 43 Koren, S., et al. PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. Nature 525 (2015), 114–118.
44. 44 Van Keymeulen, A., et al. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature 525 (2015), 119–123.
45. 45 Berquam-Vrieze, K.E., et al. Cell of origin strongly influences genetic selection in a mouse model of T-ALL. Blood 118 (2011), 4646–4656.
46. 46 Alcantara Llaguno, S.R., et al. Adult lineage-restricted CNS progenitors specify distinct glioblastoma subtypes. Cancer Cell 28 (2015), 429–440.
47. 47 Kim, T.H., et al. Broadly permissive intestinal chromatin underlies lateral inhibition and cell plasticity. Nature 506 (2014), 511–515.
48. 48 Kaaij, L.T., et al. DNA methylation dynamics during intestinal stem cell differentiation reveals enhancers driving gene expression in the villus. Genome Biol., 14, 2013, R50.
49. 49 Visvader, J.E., Clevers, H., Tissue-specific designs of stem cell hierarchies. Nat. Cell. Biol. 18 (2016), 349–355.
50. 50 Takeda, N., et al. Interconversion between intestinal stem cell populations in distinct niches. Science 334 (2011), 1420–1424.
51. 51 Tian, H., et al. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 478 (2011), 255–259.
52. 52 Yan, K.S., et al. The intestinal stem cell markers Bmi1 and Lgr5 identify two functionally distinct populations. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 466–471.
53. 53 van Es, J.H., et al. Dll1+ secretory progenitor cells revert to stem cells upon crypt damage. Nat. Cell. Biol. 14 (2012), 1099–1104.
54. 54 Lee, G.H., et al. Is right-sided colon cancer different to left-sided colorectal cancer?. A systematic review. Eur. J. Surg. Oncol. 41 (2015), 300–308.
55. 55 Missiaglia, E., et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann. Oncol. 25 (2014), 1995–2001.
56. 56 Glebov, O.K., et al. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol. Biomarkers. Prev. 12 (2003), 755–762.
57. 57 Yamauchi, M., et al. Colorectal cancer: a tale of two sides or a continuum?. Gut 61 (2012), 794–797.
58. 58 Fearon, E.R., Molecular genetics of colorectal cancer. Annu. Rev. Pathol. 6 (2011), 479–507.
59. 59 Muto, T., et al. The evolution of cancer of the colon and rectum. Cancer 36 (1975), 2251–2270.
60. 60 IJspeert, J.E., et al. Serrated neoplasia-role in colorectal carcinogenesis and clinical implications. Nat. Rev. Gastroenterol. Hepatol. 12 (2015), 401–409.
61. 61 Leggett, B., Whitehall, V., Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 138 (2010), 2088–2100.
62. 62 Snover, D.C., Update on the serrated pathway to colorectal carcinoma. Hum. Pathol. 42 (2011), 1–10.
63. 63 Jass, J.R., Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50 (2007), 113–130.
64. 64 Phipps, A.I., et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology, 148, 2015 77–87.e72.
65. 65 Fessler, E., et al. TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. EMBO Mol. Med. 8 (2016), 745–760.
66. 66 Herman, J.G., et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 6870–6875.
67. 67 Dolcetti, R., et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am. J. Pathol. 154 (1999), 1805–1813.
68. 68 Wiener, Z., et al. Oncogenic mutations in intestinal adenomas regulate Bim-mediated apoptosis induced by TGF-β. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E2229–E2236.
69. 69 Jinek, M., et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337 (2012), 816–821.
70. 70 Cho, S.W., et al. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 31 (2013), 230–232.
71. 71 Cong, L., et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339 (2013), 819–823.
72. 72 Mali, P., et al. RNA-guided human genome engineering via Cas9. Science 339 (2013), 823–826.
73. 73 Drost, J., et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature 521 (2015), 43–47.
74. 74 Matano, M., et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat. Med. 21 (2015), 256–262.
75. 75 Fujii, M., et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. Cell Stem Cell 18 (2016), 827–838.
76. 76 Egeblad, M., et al. Tumors as organs: complex tissues that interface with the entire organism. Dev. Cell 18 (2010), 884–901.
77. 77 Schwitalle, Y., et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134 (2008), 988–997.
78. 78 Waldner, M.J., Neurath, M.F., Colitis-associated cancer: the role of T cells in tumor development. Semin. Immunopathol. 31 (2009), 249–256.
79. 79 Jawad, N., et al. Inflammatory bowel disease and colon cancer. Recent Results Cancer Res. 185 (2011), 99–115.
80. 80 Becht, E., et al. Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy. Clin. Cancer. Res., 2016 (in press).
81. 81 Kalluri, R., Zeisberg, M., Fibroblasts in cancer. Nat. Rev. Cancer 6 (2006), 392–401.
82. 82 Calon, A., et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47 (2015), 320–329.
83. 83 Isella, C., et al. Stromal contribution to the colorectal cancer transcriptome. Nat. Genet. 47 (2015), 312–319.
84. 84 Fessler, E., et al. A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype. Oncogene., 2016 (in press).
85. 85 Shioiri, M., et al. Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br. J. Cancer 94 (2006), 1816–1822.
86. 86 Spaderna, S., et al. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 131 (2006), 830–840.
87. 87 Fischer, K.R., et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527 (2015), 472–476.
88. 88 Zheng, X., et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527 (2015), 525–530.
89. 89 Mesker, W.E., et al. Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cell. Oncol. 31 (2009), 169–178.
90. 90 Yamashita, M., et al. Role of stromal myofibroblasts in invasive breast cancer: stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome. Breast Cancer 19 (2012), 170–176.
91. 91 Fujita, H., et al. Alpha-smooth muscle actin expressing stroma promotes an aggressive tumor biology in pancreatic ductal adenocarcinoma. Pancreas, 2010 (in press).
92. 92 Finak, G., et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14 (2008), 518–527.
93. 93 Moffitt, R.A., et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47 (2015), 1168–1178.
94. 94 Calon, A., et al. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell 22 (2012), 571–584.
95. 95 Junttila, M.R., de Sauvage, F.J., Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501 (2013), 346–354.
96. 96 Bhargava, M., et al. Scatter factor and hepatocyte growth factor: activities, properties, and mechanism. Cell Growth Differ. 3 (1992), 11–20.
97. 97 Cheon, D.J., Orsulic, S., Mouse models of cancer. Annu. Rev. Pathol. 6 (2011), 95–119.
98. 98 Carragher, L.A., et al. V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol. Med. 2 (2010), 458–471.
99. 99 Linnekamp, J.F., et al. Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes. Cancer Res. 75 (2015), 245–249.
100. 100 Curigliano, G., New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance. Cancer Treat. Rev. 38 (2012), 303–310.
101. 101 De Sousa E Melo, F., et al. Cancer heterogeneity–a multifaceted view. EMBO Rep. 14 (2013), 686–695.
102. 102 Sequist, L.V., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med., 3, 2011 75ra26.
103. 103 Khambata-Ford, S., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25 (2007), 3230–3237.
104. 104 Lievre, A., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26 (2008), 374–379.
105. 105 Moroni, M., et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6 (2005), 279–286.
106. 106 Cappuzzo, F., et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann. Oncol. 19 (2008), 717–723.
107. 107 Laurent-Puig, P., et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol. 27 (2009), 5924–5930.
108. 108 De Roock, W., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11 (2010), 753–762.
109. 109 Douillard, J.Y., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 369 (2013), 1023–1034.
110. 110 Bertotti, A., et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 526 (2015), 263–267.
111. 111 Zanella, E.R., et al. IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. Sci. Transl. Med., 7, 2015, 272ra212.
112. 112 Sartore-Bianchi, A., et al. Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer. J. Natl. Cancer Inst., 108, 2016, djv306.
113. 113 Vecchione, L., et al. A vulnerability of a subset of colon cancers with potential clinical utility. Cell 165 (2016), 317–330.
114. 114 Vogelstein, B., Kinzler, K.W., Cancer genes and the pathways they control. Nat. Med., 10, 2004 789-779.